Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Total Current Liabilities (2016 - 2026)

Sunshine Biopharma filings provide 11 years of Total Current Liabilities readings, the most recent being $6.4 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 2.04% to $6.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.4 million, a 2.04% increase, with the full-year FY2025 number at $6.4 million, up 2.04% from a year prior.
  • Total Current Liabilities hit $6.4 million in Q4 2025 for Sunshine Biopharma, down from $6.7 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $6.9 million in Q4 2022 to a low of $91229.0 in Q4 2021.
  • Median Total Current Liabilities over the past 5 years was $5.2 million (2023), compared with a mean of $3.9 million.
  • Biggest five-year swings in Total Current Liabilities: plummeted 91.32% in 2021 and later skyrocketed 7497.38% in 2022.
  • Sunshine Biopharma's Total Current Liabilities stood at $91229.0 in 2021, then skyrocketed by 7497.38% to $6.9 million in 2022, then dropped by 19.9% to $5.6 million in 2023, then rose by 13.74% to $6.3 million in 2024, then rose by 2.04% to $6.4 million in 2025.
  • The last three reported values for Total Current Liabilities were $6.4 million (Q4 2025), $6.7 million (Q3 2025), and $5.6 million (Q2 2025) per Business Quant data.